RE: Morning top up9 Feb 2023 09:06
Metom, GDR is nothing more than a ramp imo. The product is not a cancer drug and it's not as valuable. Cancer drugs generate huge revenue worth billions if they are good. GDR needs to generate sufficient revenue or get enough cash to justify the market cap. It will drop back down.
Val on the other hand is at the bottom so should move up. Our time will come but Suzy needs to write a good RNS focussing on potential, positives and next steps.